Recent

% | $
Quotes you view appear here for quick access.

Inergy, L.P. Message Board

wilderguide 290 posts  |  Last Activity: 20 hours ago Member since: Jan 13, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Conference next week

    by voisybay Sep 23, 2016 6:01 AM
    wilderguide wilderguide 20 hours ago Flag

    $$$$
    $8 You promise...?"
    I may not always be the best at reading the tea leaves, but I understand the significance of oral presentation in a prestigious venue. Here, we have two...
    In medicine, typical acceptance of late-breaking oral presentation is determined by potential that stands to offer practice-changing data. If those data are well-received in a peer-reviewed setting such as CNS, the analysts will respond with new price targets before the week is out. If a sixth AIS grade conversion were to be announced at this venue, the SP could spike dramatically on healthy volume. The institutions haven't been accumulating for naught. Timing is everything. Stay ready.

  • Reply to

    Conference next week

    by voisybay Sep 23, 2016 6:01 AM
    wilderguide wilderguide Sep 23, 2016 5:55 PM Flag

    $$$$
    "Maybe Canada's FDA equilavent approved the NSS."
    While I think that thought a bit premature, here's what I see taking place next week...
    A case for probable benefit of NSS implant is slowly being built, and further - being supported by early witness to minimum OPC thresholds. The scrutiny for the remainder of enrollment will be the target of clinical largess - if only to safeguard preservation of existing data. Further changes to protocol may be required to best inform, and will be made to best align with validated observations of advanced imaging - a continually improving aspect of this procedure. I expect NVIV to paint the tape in the vicinity of $8 next week...with CNS 2016 data being interpreted as a huge success. All JMO...

  • wilderguide wilderguide Sep 23, 2016 2:39 PM Flag

    $$$$
    "I can't wait to learn more about those "secret" canadian patients you've been pumping."
    How else could a Health Canada-licensed neurosurgeon report on his personal surgical experience with the NSS?

    "Can I ask what value YOU bring to this board?"
    Humor. I'll keeping pumping company "secrets"...
    While you keep pumping yer pudd...

  • wilderguide wilderguide Sep 22, 2016 5:31 PM Flag

    $$$$
    Thanks for sharing your wisdom...
    Think I'll get out now, just before the NSS has two LBA oral abstracts...
    Given by independent neurosurgical reviewers...
    At one of the most prestigious neurosurgical conferences of the year...
    Thanks for saving my butt... I owe you my life...really...
    Whew!!! ....that was close...

  • wilderguide wilderguide Sep 20, 2016 11:12 AM Flag

    $$$$
    "I would say "yes" wilder. One need not be Sherlock to deduce that Canada has not only performed the procedure on one or more patient, but has enjoyed success."
    Further to this, the LBA submission deadline was 8/2/16. The Health Canada ITA was awarded on 7/13, with the first ex-US location announcement on 7/14 - making it a reasonable assumption that the first Canadian NSS patient is nearly two months into recovery - perhaps giving us a 6 month evaluation timeline before Feb 2017.
    Make no mistake, the CNS would make a great venue to announce another early conversion.

  • $$$$
    ...means there is at least one Canadian SCI recruited to the INSPIRE trial, doesn't it?
    No worries...moving right along...

  • wilderguide wilderguide Sep 20, 2016 6:50 AM Flag

    $$$$
    "in the end, most are making a mountain out of a molehill. Very good results to date..."
    I agree. There seems to be a lot of impatience with the process of peer review. Many here are too willing to hold Perrin accountable for clinical development issues that are beyond his scope as CEO. The neurosurgical community must carry the ball here as their independent review is the only review that will carry the weight of scientific validation. Further, that validation comes with specific protocols of venue and presentation. No researcher wants his work interpreted prematurely, and no researcher wants his work unveiled at any but the most appropriate venue. That's simply how it's done, and that schedule of appropriate peer-reviewed scientific presentation is completely independent of CEO concerns, trial process, or shareholder wishes. There's lots at play here that is beyond Perrin's control, if only because it's beyond his professional capacity.
    Just the way it is...

  • Reply to

    Inspire Clinical Trials Link

    by options2wealth Sep 18, 2016 11:44 AM
    wilderguide wilderguide Sep 18, 2016 4:32 PM Flag

    $$$$
    "Doesn't mean they weren't "paused"...
    Yer brain is permanently "paused"...
    You are a cubicle monkey with three speeds, biotrader: Slow, Stop & Stupid

  • wilderguide wilderguide Sep 14, 2016 6:58 PM Flag

    $$$$
    JMO, but I don't think we've accumulated enough data to add to the site-specific trial protocol, but given that OPC minimum threshold has been met this early in the trial structure, it is a possibility. If a major change to trial protocol had been applied for by NVIV, it would certainly account for the recruiting shutdown - if one has indeed taken place.

  • $$$$
    When I first posted this abstract several weeks ago, it was ha-ha'ed by Thrope as "old news"...
    Well - guess what, you moping, loping, groping dope with no hope to cope...
    These surgical big dogs don't think it's "old news"...
    Stay ready, dooshwaddle...

  • wilderguide wilderguide Aug 27, 2016 12:20 PM Flag

    $$$$
    "Essentially three months left in the year..."
    Yeah, lecture us on truth, you math wizard. There are four months remaining in the year, and truth is - each one ends in "R" : this indicates a month in which "Recruitment" likelihood is optimal. Now there's a great truth for you...
    Get off your sorry brain, go outside, and find a life...

  • wilderguide wilderguide Aug 27, 2016 12:02 PM Flag

    $$$$
    Sun Tsu says:
    Those that dispel their perceived truths on Yahoo Message Boards...
    Have no idea what truth is...

  • Reply to

    Hillary killing the entire sector

    by creedheed Aug 24, 2016 3:36 PM
    wilderguide wilderguide Aug 24, 2016 5:54 PM Flag

    $$$$
    Speaking of stuff that don't work, how's the kids? Mom & Pop OK?

  • Reply to

    Director picks up 70,000 shares

    by balmoral_design Aug 24, 2016 9:58 AM
    wilderguide wilderguide Aug 24, 2016 10:26 AM Flag

    $$$$
    "...a little poke in the eye..."
    Just like a bad penny, a zit, or a cold sore...
    You keep coming back... What's yer problem?
    Need a fresh Dydee?

  • Reply to

    Vroom! Vroom!!

    by wilderguide Aug 22, 2016 3:01 PM
    wilderguide wilderguide Aug 22, 2016 3:59 PM Flag

    $$$$
    "Anybody walking?"
    Not a trial endpoint...
    "Anybody moving?"
    Some more than others...
    Stick to the published trial endpoints, and you'll better understand what happens next...
    My questions to you - Anybody converting - as defined by AIS criteria?
    Seen any peer reviewed publications noting a high AIS conversion rate wrt INSPIRE?
    See any notable institutions participating in INSPIRE? See anything at all...???
    Other than the lack of light in yer patootie?
    Need a snorkel?

  • wilderguide by wilderguide Aug 22, 2016 3:01 PM Flag

    $$$$
    Somebody musta stolen the front spoke balloons outta Thrope's BMX...

  • wilderguide wilderguide Aug 20, 2016 9:33 PM Flag

    $$$$
    Further to this discussion, for the first time since that 2/29/16 PR, the NSS may be considered to have attained the minimum requirements for an HUD filing - a necessary prerequisite to an HD exemption. While in itself no guarantee of commercial prospect, a well-deserved HDE will definitively boost future enrollment and pay the rent. Another conversion or two in the coming months could easily "ice" any question of probable benefit, and also holds the promise to pick up the tab for ongoing research. The Feds might even see the promise in stem cell integration - from there, it becomes anyone's guess. This one's up in the air, and I intend to play it as a winner...

  • wilderguide wilderguide Aug 20, 2016 5:55 PM Flag

    $$$$
    The following excerpt is from the 2/29 Invivo PR updating the INSPIRE study protocol:
    "The OPC for The INSPIRE Study is defined as 25% or more of the patients in the study demonstrating an improvement of at least one ASIA Impairment Scale (AIS) grade by six months post-implantation. Since The INSPIRE Study is designed to enroll 20 patients with complete (AIS A) spinal cord injuries (inclusive of the 5 patients enrolled in the company’s pilot trial) the OPC equates to having five patients convert to any other AIS grade by six months post-implantation. Natural history databases indicate that between 12-16% of patients with complete (AIS A) thoracic injury will spontaneously convert without treatment six months after injury."
    Though I am optimistic with results to date, I see no easy path to early approval. Final assessments will be made based upon all the endpoint criteria, and the PR goes on to outline that final HDE consideration-making will not be based solely on AIS conversion data...but also to include data beyond baseline OPC. There's still a long path forward, and this past week's news - though very positive - is far from end of story. The coming year should be loaded with great trading catalysts. I am building a core position, trading as opportunity presents...

  • wilderguide by wilderguide Aug 19, 2016 1:28 PM Flag

    $$$$
    ...is best left to the mentally competent. GLTA

  • Reply to

    New NCI trial

    by wilderguide Aug 16, 2016 4:29 PM
    wilderguide wilderguide Aug 17, 2016 3:04 PM Flag

    $$$$
    "What, in your opinion, is the size of the market for these indications...?"
    IMO, very small...if looked at individually. In the aggregate, the tax incentives derived from developing Cabo as an orphan drug candidate could provide substantial savings to overall development costs. Most of the diseases addressed in this NCI-sponsored trial are orphan indications, and Cabo has already seen some limited off label prescription in several of those listed.